Predictive Role of Metabolic Profiling in Rivaroxaban Efficacy for Thrombus Lysis in Atrial Fibrillation
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms262110757 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Sylwia Michorowska und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Drug Chemistry, Pharmaceutical and Biomedical Analysis, Faculty of Pharmacy, Medical University of Warsaw, 02-097 Warsaw, Poland. Hauptthemen laut MEDLINE: Rivaroxaban, Atrial Fibrillation, Thrombosis, Metabolomics. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Warsaw.
Abstract (Originalsprache)
Traditional anticoagulants used in atrial fibrillation (AF) are being increasingly replaced by novel oral anticoagulants such as rivaroxaban, improving patient outcomes. Although rivaroxaban 20 mg/1× daily is approved to reduce stroke and systemic embolism risk in AF, some patients still develop thrombus in the left atrial appendage (LAA). A previous study demonstrated thrombus lysis with a modified regimen of rivaroxaban 15 mg/2× daily, yet over 50% of patients remained unresponsive despite therapeutic plasma levels. This study compared metabolic profiles of responders and non-responders to identify predictive markers of treatment efficacy. From the RIVA-TWICE study cohort (n = 249), 15 AF patients with LAA thrombus despite standard dosing were switched to 2 × 15 mg rivaroxaban. Plasma samples collected prior to dose modification underwent untargeted and targeted LC-MS analysis, focusing on acylcarnitines (ACs), carnitine, and its precursors. Thrombus resolution occurred in 7 (46.7%) patients, who showed differential abundance of metabolites related to alpha-linolenic acid and fatty acid metabolism, carnitine synthesis, and arginine/proline pathways. Targeted analysis confirmed elevated levels of ACs, carnitine, and precursors. Findings suggest that a patient phenotype, including carnitine, its precursors, and ACs, may predict rivaroxaban efficacy in thrombus lysis. While these metabolites may not directly mediate lysis, their elevated levels represent potential biomarkers of treatment response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Drug Chemistry, Pharmaceutical and Biomedical Analysis, Faculty of Pharmacy, Medical University of Warsaw, 02-097 Warsaw, Poland.
- Department of Cardiology, Postgraduate Medical School, Grochowski Hospital, 04-073 Warsaw, Poland.
ORCID-Profile: Natalia Korytowska-Przybylska, Roman Piotrowski, Piotr Kułakowski, Joanna Giebułtowicz
Förderung
- Medical University of Warsaw
Zitieren
APA
Michorowska, S., Korytowska-Przybylska, N., Piotrowski, R., Kułakowski, P., & Giebułtowicz, J. (2025). Predictive Role of Metabolic Profiling in Rivaroxaban Efficacy for Thrombus Lysis in Atrial Fibrillation. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262110757
Vancouver
Michorowska S, Korytowska-Przybylska N, Piotrowski R, Kułakowski P, Giebułtowicz J. Predictive Role of Metabolic Profiling in Rivaroxaban Efficacy for Thrombus Lysis in Atrial Fibrillation. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262110757
BibTeX
@article{Michorowska2025,
author = {Michorowska, Sylwia and Korytowska-Przybylska, Natalia and Piotrowski, Roman and Kułakowski, Piotr and Giebułtowicz, Joanna},
title = {Predictive Role of Metabolic Profiling in Rivaroxaban Efficacy for Thrombus Lysis in Atrial Fibrillation},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms262110757}
}
EUVIMED